Email this article Endometriosis in perimenopausal transition period and in postmenopause: clinical, diagnostic and therapeutic aspects
- Authors: Kalinkina O.B.1, Tezikov Y.V.1, Lipatov I.S.1, Aravina O.R.1, Martynova N.V.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 4, No 1 (2019)
- Pages: 4-7
- Section: Obstetrics and Gynecology
- URL: https://ogarev-online.ru/2500-1388/article/view/43725
- DOI: https://doi.org/10.35693/2500-1388-2019-4-1-4-7
- ID: 43725
Cite item
Full Text
Abstract
Objectives – efficiency assessment of the dienogest (Visannе) in treatment of perimeopausal patients with adenomyosis and postmenopausal women, in whom the adenomyosis was newly diagnosed.
Material and methods. Included in the study, there were 64 patients (aged 45–52 years) who had undergone the surgical treatment of adenomyosis followed by the dienogest treatment at a dose of 2 mg, and 47 women in the age of 54–57 years with newly diagnosed adenomyosis in the course of menopausal hormone therapy (MHT). All patients received 2 mg of dienogest (Visannе, Bayer) during the period of 3–6 months. Medical checkup was performed in 3 and 6 months after initiation of treatment.
Results and Discussion. The remarkable reduction in clinical manifestations and improvement of uterine walls structure was registered in both groups of patients in 3 months of treatment. However, in 25% of patients the echographic changes remained significant. In 6 months all the patients had a sustained remission and amenorrhea.
Conclusion. In the course of investigation the dienogest (Visannе) at a dose of 2 mg revealed high efficacy in treatment of endometriosis in late perimeopausal and postmeopausal patients with a diagnosed abnormal uterine bleeding associated with adenomyosis.
Full Text
##article.viewOnOriginalSite##About the authors
Ol'ga B. Kalinkina
Samara State Medical University
Email: maiorof@mail.ru
ORCID iD: 0000-0002-1828-3008
PhD, Associate Professor, Professor, obstetrics and gynecology chair №1 of the SamSMU
Russian Federation, SamaraYurii Vladimirovich Tezikov
Samara State Medical University
Author for correspondence.
Email: yra.75@inbox.ru
ORCID iD: 0000-0002-8946-501X
PhD, Professor, Head of chair №1 of obstetrics and gynecology of the SamSMU
Russian Federation, SamaraIgor' S. Lipatov
Samara State Medical University
Email: i.lipatoff2012@yandex.ru
ORCID iD: 0000-0001-7277-7431
PhD, Professor, Professor of chair №1 of obstetrics and gynecology of the SamSMU
Russian Federation, SamaraOksana R. Aravina
Samara State Medical University
Email: dr.aravina@gmail.com
ORCID iD: 0000-0002-2107-1508
teaching assistant of obstetrics and gynecology chair №1 of the SamSMU
Russian Federation, SamaraNadezhda V. Martynova
Samara State Medical University
Email: nadya-martynova@yandex.ru
ORCID iD: 0000-0003-2762-9346
clinical resident of obstetrics and gynecology chair №1 of the SamSMU
Russian Federation, SamaraReferences
- Кузнецова И.В., Ховрина Е.А., Кирпиков А.С. Возможности применения комбинированных оральных контрацептивов у больных генитальным эндометриозом. Гинекология. 2012;14(5):17–21. [Kuznecova IV, Hovrina EA, Kirpikov AS. Combined oral contraceptive pill in patients with genital endometriosis. Ginekologija. 2012;14(5):17–21. (In Russ.)].
- Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann NY Acad Sci. 2002 Mar.;955:11–22; discussion 34–6, 396–406. doi: 10.4324/9780203319390_chapter_4
- Bulun SE. Endometriosis. N Engl J Med. 2009; 360:268. doi: 10.1056/nejmra0804690
- Bisboff F, Heard M, Simpson J. Somatic DNA alterations in endometriosis: High frequency of chromosome 17 and p53 loss in late stage endometriosis. J Reprod Immunol. 2002;55:49–64. doi: 10.1016/s0165-0378(01)00131-0
- Gemmell LC, Webster KE. Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017;23(4):481–500. doi: 10.1093/humupd/dmx011
- Osteen K, Bruner-Tran K, On D et al. Paracrine mediators of endometrial matrix metalloproteinase expression: Potential targets for progestin-based treatment of endometriosis. Ann NYAcad Sci. 2002; 955:139–46. doi: 10.1111/j.1749-6632.2002.tb02774
- Van Kaam KJAF, Romano A, Schouten JP et al. Progesterone receptor polymorphism +331G/A is associated with a decreased risk of deep infiltrating endometriosis. Hum reprod. 2006;22(1):129–35. doi: 10.1093/humrep/del325
- Giudice LС, Као LC. Endometriosis. Lancet. 2004; 364: 1789–99. doi: 10.1016/s0140-6736(04)17403-5
- Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev. 2009;Cd005997. doi: 10.1002/14651858.CD005997.pub2
- Momoeda M, Harada T, Terakawa N et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol. Res. 2009;35:1069–76. doi: 10.1111/j.1447-0756.2009.01076
- Kives S, Brown J, Prentice A, Deary A, Bland ES. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews. 2000, Issue 2. Art. No.: CD002122. doi: 10.1002/14651858.CD002122
- Fu L, Osuga Y, Hirata T et al. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertil Steril. 2008;89:1344–7. doi: 10.1016/j.fertnstert.2007.03.042
- Калинкина О.Б, Тезиков Ю.В., Тезикова Т.А. и др. Эффективность терапии пациенток с эндометриоидными кистами яичников. Аспирантский вестник Поволжья. 2016;1–2:21–26. [Kalinkina OB, Tezikov YuV, Tezikova TA et al. Effektivnost' terapii pacientok s ehndometrioidnymi kistami yaichnikov [Effectivness of the therapy of patients with ovarian endometriotic cysts]. Aspirantskij vestnik Povolzh'ya. 2016;1–2:21–26. (In Russ.)].
Supplementary files
